KAINOS MEDICINE, INC. Logo

KAINOS MEDICINE, INC.

Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.

284620 | KO

Overview

Corporate Details

ISIN(s):
KR7284620002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로 700 코리아바이오파크 제3층 제에이-301호 일부, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Kainos Medicine, Inc. is a clinical-stage research and development company specializing in the discovery of innovative medicines. The firm's primary focus is on developing novel small molecule therapeutics to address unmet medical needs in neurodegenerative disorders, cancers, and infectious diseases. Its drug pipeline includes candidates for the treatment of conditions such as Parkinson's disease, multiple system atrophy (MSA), and AIDS. The company advances its portfolio through both independent research and strategic collaborations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (다계통 위축증(MSA) 치료신약 KM-819의 임상 2상 …
Korean 26.9 KB
2025-09-05 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.3 MB
2025-09-05 00:00
Interim Report
[기재정정]반기보고서 (2025.06)
Korean 1.4 MB
2025-09-05 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-09-03 00:00
Earnings Release
[기재정정]반기또는분기매출액미달사실발생
Korean 14.3 KB
2025-09-01 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 13.2 KB
2025-08-18 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.0 KB
2025-08-18 00:00
Audit Report / Information
[기재정정]반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 16.6 KB
2025-08-18 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 5.6 KB
2025-08-14 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 9.4 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련)
Korean 2.9 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB

Automate Your Workflow. Get a real-time feed of all KAINOS MEDICINE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KAINOS MEDICINE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KAINOS MEDICINE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Atomera Inc Logo
Licenses semiconductor material and IP to enhance transistor performance and power efficiency.
United States of America
ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan
6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia
AEE
Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing IL-1β therapies for immune inflammatory diseases.
United States of America
AVTX
AVIS BUDGET GROUP, INC. Logo
Global provider of car rental, truck rental, and car-sharing for business & leisure travelers.
United States of America
CAR
Azenta, Inc. Logo
Life science solutions for pharma & biotech, offering sample management, storage & multiomics.
United States of America
AZTA
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan
6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom
BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden
BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.